Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models.

Area of Science:

• Oncology
• Biotechnology
• Preclinical Research

Background:

• Breast cancer, particularly triple-negative subtypes, lacks effective treatment strategies and adequate preclinical models.
• Tumor microenvironment complexity hinders the development of targeted therapies for diverse breast cancer subtypes.
• Current animal models often fail to replicate patient-specific breast cancer nuances.

Purpose of the Study:

• To review advanced in vitro tumor models for breast cancer research.
• To discuss the potential and limitations of these models as patient-specific preclinical tools.
• To highlight tumor-on-chip technologies for studying the tumor microenvironment.

Main Methods:

• Review of current literature on in vitro tumor models, focusing on breast cancer applications.
• Analysis of tumor-on-chip technologies incorporating stroma, vasculature, and immune cells.
• Evaluation of models for studying metastasis, multi-organ interactions, and drug efficacy/toxicity.

Main Results:

• In vitro tumor models, especially tumor-on-chip systems, provide precise control over the tumor microenvironment.
• These advanced models can better mimic human physiology and patient-specific tumor characteristics.
• Tumor-on-chip technologies show potential in evaluating drug efficacy and toxicity in humanized systems.

Conclusions:

• Advanced in vitro tumor models are crucial for bridging the gap between current preclinical limitations and human biology.
• Tumor-on-chip technologies represent a significant advancement in breast cancer preclinical research.
• These models offer a promising avenue for developing personalized treatments, particularly for aggressive breast cancer subtypes.